Check Out 3 High-Yielding Dividend Stocks In Real Estate Sector From Wall Street's Most Accurate Analysts

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy. Here's a look at the most recent high-yield dividend stock ratings from the most accurate Wall Street analysts, according to Benzinga's Analyst Stock Ratings.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.

SL Green Realty Corp. SLG

• Dividend Yield: 10.20%
• BMO Capital analyst John Kim upgraded the stock from Market Perform to Outperform with a price target of $30 on April 3, 2023. This analyst has an accuracy rate of 67%.
• Morgan Stanley analyst Ronald Josey maintained an Equal-Weight rating and cut the price target from $35 to $21 on March 31, 2023. This analyst has an accuracy rate of 70%.
• Recent News: SL Green Realty recently sold its 49.9% stake in the 245 Park Avenue property at a $2 billion valuation.

Sabra Health Care REIT, Inc. SBRA

• Dividend Yield: 9.46%
• Citigroup analyst Nicholas Joseph maintained a Neutral rating and raised the price target from $11 to $12.5 on July 14, 2023. This analyst has an accuracy rate of 63%.
• Credit Suisse analyst Omotayo Okusanya reiterated a Neutral rating with a price target of $13 on April 12, 2023. This analyst has an accuracy rate of 61%.
• Recent News: Sabra Health Care REIT posted better-than-expected quarterly sales.

Global Medical REIT Inc. GMRE

• Dividend Yield: 8.55%
• B. Riley Securities analyst Bryan Maher maintained a Buy rating and cut the price target from $12 to $11 on May 8, 2023. This analyst has an accuracy rate of 66%.
• BMO Capital analyst John Kim downgraded the stock from Outperform to Market Perform and cut the price target from $13 to $9 on Oct. 6, 2022. This analyst has an accuracy rate of 67%.
• Recent News: Global Medical REIT posted downbeat first-quarter sales.

Read More: Top 5 Tech And Telecom Stocks That May Implode This Quarter